Pembrolizumab delivered intravenously every 3 weeks for 1 year extended recurrence-free survival (RFS) in patients with resected stage III melanoma, according to results of the KEYNOTE-054/EORTC 1325-MG* trial.
The next-generation TKI* alectinib maintains lung cancer symptoms for a longer duration than crizotinib, the current standard of care for patients with ALK-positive non-small–cell lung cancer (NSCLC), according to new data from the ALEX** study presented at ELCC 2018.
Patients with locally advanced hepatocellular carcinoma (HCC) from the Asia Pacific region had comparable overall survival (OS) regardless of whether they were treated with selective internal radiation therapy (SIRT) or sorafenib. However, SIRT appeared to be more tolerable than sorafenib, according to results of the phase III SIRveNIB* trial.
Post-menopausal women diagnosed with oestrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery followed by whole breast radiotherapy have a reduced risk of developing local recurrence, according to a study from Italy.
The first-line use of osimertinib in patients with EGFR mutation–positive advanced non-small-cell lung cancer (NSCLC) is associated with significant improvements in a number of post-progression endpoints compared with current standard of care (SoC), according to new data from the phase III FLAURA study.
The addition of low-dose cisplatin plus fluorouracil hepatic arterial infusion chemotherapy to sorafenib provides no additional survival benefit over sorafenib alone for patients with advanced, unresectable hepatocellular carcinoma, a recent randomized phase III study has shown.
Infants delivered via caesarean section may be at increased risk of developing acute lymphoblastic leukaemia, according to a US study. Altered microbiota colonization is a possible explanation for this risk, although clear biological mechanisms have yet to be established.
Hybrid capture-based comprehensive genomic profiling (CGP) may have the capability to detect epidermal growth factor receptor (EGFR) point mutations in non-small cell lung cancer (NSCLC) that were missed by standard-of-care molecular EGFR testing, a recent study found.
High use of hydrochlorothiazide (HCTZ) appears to significantly increase the risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), suggests a recent study. Use of other diuretic and antihypertensive medications does not appear to be linked to NMSC.
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).